Emerald Health Pharmaceuticals Initiates Phase I Clinical Study on its Oral Drug Candidate Derived from Cannabidiol
27. September 2018 08:00 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a company developing medicines based on cannabinoid science, today announced the initiation of enrollment...
Emerald Health Pharmaceuticals Announces Publications on Patented Cannabinoid Derivatives to Treat Scleroderma and Amyotrophic Lateral Sclerosis
24. September 2018 08:00 ET
|
Emerald Health Pharmaceuticals
Preclinical data published in Biochemical Pharmacology and British Journal of Pharmacology highlight neuroprotective, anti-fibrotic, and anti-inflammatory effects SAN DIEGO, CA, Sept. 24, 2018 ...
Emerald Health Pharmaceuticals to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
28. August 2018 08:00 ET
|
Emerald Health Pharmaceuticals
San Diego, CA, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a company developing medicines based on cannabinoid science, today announced that Jim DeMesa, MD, Chief...